Serological response and poliovirus excretion following different combined oral and inactivated poliovirus vaccines immunization schedules

Vaccine

Volumn 21, Issue 15, 2003, Pages 1710-1718

  Du Châtelet, Isabelle Parent ^a   Merchant, Anwar T ^b,e   Fisher Hoch, Susan ^b,f   Luby, Stephen P ^b,g   Plotkin, Stanley A ^c   Moatter, Tariq ^b   Agboatwalla, Mubina ^d   Mc Cormick, Joseph B ^b,f  

^a Assoc pour l'Aide a la Med Prev   (France)

^b AGA KHAN UNIVERSITY   (Pakistan)

^c Aventis Pasteur   (United States)

^d CIVIL HOSPITAL   (Pakistan)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^g CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Immunogenicity; OPV IPV combination; Poliomyelitis

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; INACTIVATED VACCINE; POLIOMYELITIS VACCINE;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEVELOPING COUNTRY; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; INFANT; INTESTINE; MAJOR CLINICAL STUDY; MUCOSAL IMMUNITY; NEWBORN; PAKISTAN; POLIOMYELITIS; POLIOMYELITIS VIRUS; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; SEROLOGY; VIRUS EXCRETION;

ANTIBODIES, VIRAL; CHILD, PRESCHOOL; FECES; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNIZATION SCHEDULE; INFANT; INFANT, NEWBORN; POLIOVIRUS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL; SEROEPIDEMIOLOGIC STUDIES; VACCINES, COMBINED;

EID: 0037413978     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00523-6     Document Type: Article

References (29)

1. World Health Assembly GSWHO. Global Eradication of Poliomyelitis by the year 2000: resolution of the 41st World Health Assembly. Geneva (Switzerland): World Health Organization, 1988 (Resolution WHA41 28).
2. Chen R.T., Hausinger S., Dajani A.S., Hanfling M., Baughman A.L., Pallansch M.A.et al. Seroprevalence of antibody against poliovirus in inner-city preschool children: implications for vaccination policy in the United States. JAMA. 275(21):1996;1639-1645.
3. Mas L.P., Ramon B.J., Andrus J.K., Comellas M.M., Galindo M.A., de Quadros C.A.et al. Lessons from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies. Bull. World Health Organ. 72(2):1994;221-225.
4. Factors affecting the immunogenicity of oral poliovirus vaccine: a prospective evaluation in Brazil and the Gambia. World Health Organization Collaborative Study Group on oral poliovirus vaccine. J Infect Dis 1995;171(5):1097-106.
5. Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. WHO Collaborative Study Group on oral and inactivated poliovirus vaccines. J Infect Dis 1997;175(Suppl 1):S215-7.
6. Biellik R.J., Allies T., Woodfill C.J., Lobanov A. Polio outbreaks in Namibia, 1993-1995: lessons learned. J. Infect. Dis. 175(Suppl 1):1997;S30-S36.
7. Al Dhahry S.H., Koul R.L., Al Busaidy S.M., Al Awaidy S.T., Al Khusaiby S.M., Suleman A.J. Poliomyelitis in Oman. Part I. The last outbreak? Acta Trop. 80(2):2001;125-130.
8. Reichler M.R., Aslanian R., Lodhi Z.H., Latif I., Khan M.A., Chaudhry R.et al. Evaluation of oral poliovirus vaccine delivery during the 1994 national immunization days in Pakistan. J. Infect. Dis. 175(Suppl 1):1997;S205-S209.
9. Wkly Epidemiol Rec 2000;75(49):397-408.
10. Progress toward poliomyelitis eradication - Pakistan, 1994-1998. Morb Mortal Wkly Rep 1999;48(6):121-26.
11. Patriarca P.A., Linkins R.W., Sutter R.W., Orenstein W.A., Optimal schedule for the administration of oral poliovirus vaccine. In: Kurstak E, editor. Measles and poliomyelitis vaccine, immunization, and control. Berlin: Springer, 1993. p. 303-13.
12. Vidor E., Caudrelier P., Plotkin S. The place of DPT/eIPV vaccine in routine pediatric vaccination. Rev. Med. Virol. 4:1994;261-277.
13. Murdin A.D., Barreto L., Plotkin S. Inactivated poliovirus vaccine: past and present experience. Vaccine. 14(8):1996;735-746.
14. Rumke H.C., Oostvogel P.M., van Steenis G., van Loon A.M. Poliomyelitis in The Netherlands: a review of population immunity and exposure between the epidemics in 1978 and 1992. Epidemiol. Infect. 115(2):1995;289-298.
15. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 1997;46(No RR03;001):1-25.
16. Tulchinsky T., Abed Y., Shaheen S., Toubassi N., Sever Y., Schoenbaum M.et al. A ten-year experience in control of poliomyelitis through a combination of live and killed vaccines in two developing areas. Am. J. Public Health. 79(12):1989;1648-1652.
17. Ion-Nedelcu N., Strebel P.M., Toma F., Biberi-Moroeanu S., Combiescu M., Persu A.et al. Sequential and combined use of inactivated and oral poliovirus vaccines: Dolj District, Romania, 1992-1994. J. Infect. Dis. 175(Suppl 1):1997;S241-S246.
18. Moriniere B.J., van Loon F.P., Rhodes P.H., Klein-Zabban M.L., Frank-Senat B., Herrington J.E.et al. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine. Lancet. 341(8860):1993;1545-1550.
19. Sutter R.W., Suleiman A.J., Malankar P., Al Khusaiby S., Mehta F., Clements G.B.et al. Trial of a supplemental dose of four poliovirus vaccines. N. Engl. J. Med. 343(11):2000;767-773.
20. Goldblum N., Gerichter C.B., Tulchinsky T.H., Melnick J.L. Poliomyelitis control in Israel, the West Bank and Gaza Strip: changing strategies with the goal of eradication in an endemic area. Bull. World Health Organ. 72(5):1994;783-796.
21. Hovi T., Stenvik M., Agboatwalla M. Effect of administering oral and inactivated polio vaccines immediately after birth. Eur. J. Clin. Microbiol. Infect. Dis. 18(7):1999;526-528.
22. Patriarca P.A., Wright P.F., John T.J. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev. Infect. Dis. 13(5):1991;926-939.
23. Kok P.W., Leeuwenburg J., Tukei P., van Wezel A.L., Kapsenberg J.G., van Steenis G. Serological and virological assessment of oral and inactivated poliovirus vaccines in a rural population in Kenya. Bull. World Health Organ. 70(1):1992;93-103.
24. Patriarca P.A., Sutter R.W., Oostvogel P.M. Outbreaks of paralytic poliomyelitis, 1976-1995. J. Infect. Dis. 175(Suppl 1):1997;S165-S172.
25. Faden H., Duffy L., Sun M., Shuff C. Long-term immunity to poliovirus in children immunized with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines. J. Infect. Dis. 168(2):1993;452-454.
26. Plotkin SA, Murdin A, Vidor E, Inactivated polio vaccine. In: Saunders, editor. Vaccines, third ed., 1999. p. 345-63.
27. Hull H.F., Lee J.W. Sabin, Salk, or sequential? Lancet. 347(9002):1996;630.
28. World Bank. World Development Report, 1993: Investing in Health. Oxford (England): Oxford University Press, 1993.
29. Yang C.F., De L., Yang S.J., Ruiz G.J., Cruz J.R., Holloway B.P.et al. Genotype-specific in vitro amplification of sequences of the wild type 3 polioviruses from Mexico and Guatemala. Virus Res. 24(3):1992;277-296.